242 related articles for article (PubMed ID: 20676138)
1. Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.
Lu C; Everhart L; Tilan J; Kuo L; Sun CC; Munivenkatappa RB; Jönsson-Rylander AC; Sun J; Kuan-Celarier A; Li L; Abe K; Zukowska Z; Toretsky JA; Kitlinska J
Oncogene; 2010 Oct; 29(41):5630-42. PubMed ID: 20676138
[TBL] [Abstract][Full Text] [Related]
2. Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance.
Czarnecka M; Trinh E; Lu C; Kuan-Celarier A; Galli S; Hong SH; Tilan JU; Talisman N; Izycka-Swieszewska E; Tsuei J; Yang C; Martin S; Horton M; Christian D; Everhart L; Maheswaran I; Kitlinska J
Oncogene; 2015 Jun; 34(24):3131-43. PubMed ID: 25132261
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors.
Kitlinska J; Abe K; Kuo L; Pons J; Yu M; Li L; Tilan J; Everhart L; Lee EW; Zukowska Z; Toretsky JA
Cancer Res; 2005 Mar; 65(5):1719-28. PubMed ID: 15753367
[TBL] [Abstract][Full Text] [Related]
4. Neuropeptide Y (NPY) in tumor growth and progression: Lessons learned from pediatric oncology.
Tilan J; Kitlinska J
Neuropeptides; 2016 Feb; 55():55-66. PubMed ID: 26549645
[TBL] [Abstract][Full Text] [Related]
5. Neuropeptide Y Y5-receptor activation on breast cancer cells acts as a paracrine system that stimulates VEGF expression and secretion to promote angiogenesis.
Medeiros PJ; Jackson DN
Peptides; 2013 Oct; 48():106-13. PubMed ID: 23932937
[TBL] [Abstract][Full Text] [Related]
6. Neuropeptide Y stimulates proliferation and migration in the 4T1 breast cancer cell line.
Medeiros PJ; Al-Khazraji BK; Novielli NM; Postovit LM; Chambers AF; Jackson DN
Int J Cancer; 2012 Jul; 131(2):276-86. PubMed ID: 21823118
[TBL] [Abstract][Full Text] [Related]
7. Neuropeptide Y as a Biomarker and Therapeutic Target for Neuroblastoma.
Galli S; Naranjo A; Van Ryn C; Tilan JU; Trinh E; Yang C; Tsuei J; Hong SH; Wang H; Izycka-Swieszewska E; Lee YC; Rodriguez OC; Albanese C; Kitlinska J
Am J Pathol; 2016 Nov; 186(11):3040-3053. PubMed ID: 27743558
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growth-inhibitory to growth-promoting effects.
Tilan JU; Lu C; Galli S; Izycka-Swieszewska E; Earnest JP; Shabbir A; Everhart LM; Wang S; Martin S; Horton M; Mahajan A; Christian D; O'Neill A; Wang H; Zhuang T; Czarnecka M; Johnson MD; Toretsky JA; Kitlinska J
Oncotarget; 2013 Dec; 4(12):2487-501. PubMed ID: 24318733
[TBL] [Abstract][Full Text] [Related]
9. Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells.
Ruscica M; Dozio E; Boghossian S; Bovo G; Martos Riaño V; Motta M; Magni P
Endocrinology; 2006 Mar; 147(3):1466-73. PubMed ID: 16339211
[TBL] [Abstract][Full Text] [Related]
10. Neuropeptide y and neuropeptide y y5 receptor interaction restores impaired growth potential of aging bone marrow stromal cells.
Igura K; Haider HKh; Ahmed RP; Sheriff S; Ashraf M
Rejuvenation Res; 2011 Aug; 14(4):393-403. PubMed ID: 21595512
[TBL] [Abstract][Full Text] [Related]
11. Neuropeptide Y promotes beta-cell replication via extracellular signal-regulated kinase activation.
Cho YR; Kim CW
Biochem Biophys Res Commun; 2004 Feb; 314(3):773-80. PubMed ID: 14741702
[TBL] [Abstract][Full Text] [Related]
12. Effects of the neuropeptide Y Y2 receptor antagonist BIIE0246 on sympathetic transmitter release in the pig in vivo.
Malmström RE; Lundberg JN; Weitzberg E
Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):106-11. PubMed ID: 11819028
[TBL] [Abstract][Full Text] [Related]
13. Neuropeptide Y receptor interactions regulate its mitogenic activity.
Czarnecka M; Lu C; Pons J; Maheswaran I; Ciborowski P; Zhang L; Cheema A; Kitlinska J
Neuropeptides; 2019 Feb; 73():11-24. PubMed ID: 30503694
[TBL] [Abstract][Full Text] [Related]
14. Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice.
Lee EW; Grant DS; Movafagh S; Zukowska Z
Peptides; 2003 Jan; 24(1):99-106. PubMed ID: 12576090
[TBL] [Abstract][Full Text] [Related]
15. Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus.
Silva AP; Carvalho AP; Carvalho CM; Malva JO
Neuropharmacology; 2003 Feb; 44(2):282-92. PubMed ID: 12623227
[TBL] [Abstract][Full Text] [Related]
16. Functional consequences of neuropeptide Y Y 2 receptor knockout and Y2 antagonism in mouse and human colonic tissues.
Hyland NP; Sjöberg F; Tough IR; Herzog H; Cox HM
Br J Pharmacol; 2003 Jun; 139(4):863-71. PubMed ID: 12813010
[TBL] [Abstract][Full Text] [Related]
17. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
[TBL] [Abstract][Full Text] [Related]
18. Characterization of NPY Y2 receptor protein expression in the mouse brain. II. Coexistence with NPY, the Y1 receptor, and other neurotransmitter-related molecules.
Stanić D; Mulder J; Watanabe M; Hökfelt T
J Comp Neurol; 2011 May; 519(7):1219-57. PubMed ID: 21452195
[TBL] [Abstract][Full Text] [Related]
19. Irreversible binding kinetics of neuropeptide Y ligands to Y2 but not to Y1 and Y5 receptors.
Dautzenberg FM; Neysari S
Pharmacology; 2005 Dec; 75(1):21-9. PubMed ID: 15908753
[TBL] [Abstract][Full Text] [Related]
20. Neuropeptide Y, a paracrine factor secreted by cancer cells, is an independent regulator of angiogenesis in colon cancer.
Chakroborty D; Goswami S; Fan H; Frankel WL; Basu S; Sarkar C
Br J Cancer; 2022 Nov; 127(8):1440-1449. PubMed ID: 35902640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
